Quizartinib

Target: This ligand targets FMS-like tyrosine kinase 3 (FLT3) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for FMS-like tyrosine kinase 3 (FLT3). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings FMS-like tyrosine kinase 3 (FLT3) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• FLT3 PROTAC Design: Quizartinib is a potent FLT3 kinase inhibitor and can serve as a high-affinity ligand for building FLT3-targeting PROTACs. By conjugating it to an E3 ligase recruiter, researchers can drive ubiquitination and proteasomal degradation of FLT3, enabling studies of degradation-dependent signaling suppression beyond kinase inhibition.

• Degradation-Driven Signaling Studies: FLT3 PROTACs incorporating Quizartinib can be used to dissect how targeted protein degradation reshapes downstream pathways such as STAT5 and MAPK. Comparing degradation potency with inhibition-only controls helps clarify whether phenotypes arise from reduced FLT3 abundance, altered receptor dynamics, or compensatory feedback mechanisms.

• Resistant FLT3 Variant Targeting: Quizartinib-based PROTACs can be leveraged to evaluate degradation efficacy against FLT3 mutants that confer resistance to conventional inhibitors. This application supports systematic testing of whether recruiting the ubiquitin-proteasome system overcomes altered binding landscapes and maintains degradation of clinically relevant FLT3 forms in cellular models.

• E3 Ligase Recruitment Optimization: The Quizartinib ligand enables PROTAC optimization by varying E3 ligase recruiters and linker architectures to maximize ternary complex formation and degradation efficiency. Researchers can screen ligase choices to identify conditions that produce robust FLT3 turnover, reduced signaling, and improved selectivity across kinases and related receptor family members.

Quizartinib is a multi-kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Quizartinib is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.